The multifaceted character of lymphotoxin β in inflammatory myopathies and muscular dystrophies

Neuromuscular Disorders

Volumn 22, Issue 8, 2012, Pages 712-719

  Creus, Kim K ^a   De Paepe, Boel ^a   Weis, Joachim ^b   De Bleecker, Jan L ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Dermatomyositis; Inflammatory myopathy; Lymphotoxin ; Muscular dystrophy; Polymyositis; Sporadic inclusion body myositis

Indexed keywords

LYMPHOTOXIN BETA; LYMPHOTOXIN BETA RECEPTOR;

ARTICLE; CELL DAMAGE; CELL NUCLEUS; CELL REGENERATION; CELL TYPE; CONTROLLED STUDY; DERMATOMYOSITIS; DUCHENNE MUSCULAR DYSTROPHY; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INCLUSION BODY MYOSITIS; INFLAMMATORY CELL; MUSCLE CELL; MUSCLE DENERVATION; MUSCLE FUNCTION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

BIOLOGICAL MARKERS; BIOPSY; HUMANS; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN-BETA; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MYOFIBRILS; MYOSITIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84863881456     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2012.04.012     Document Type: Article

References (40)

1. Dalakas M.C. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Rheumatol 2010, 10:346-352.
2. De Bleecker J.L., Engel A.G., Butcher E.C. Peripheral lymphoid tissue-like adhesion molecule expression in nodular infiltrates in inflammatory myopathies. Neuromusc Disord 1996, 6:255-260.
3. López de Padilla C.M., Vallejo A.N., Lacomis D., McNallan K., Reed A.M. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum 2009, 60:1160-1172.
4. Greenberg S.A., Pinkus J.L., Pinkus G.S., et al. Interferon-α/β mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005, 57:664-678.
5. Askanas V., Engel W.K., Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009, 19:493-506.
6. Schneider K., Potter K.G., Ware C.F. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol Rev 2004, 202:49-66.
7. Young J., Yu X., Wolslegel K., et al. Lymphotoxin-αβ heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine 2010, 51:78-86.
8. Clark J., Vagenas P., Panesar M., Cope A.P. What does tumour necrosis factor excess do to the immune system long-term?. Ann Rheum Dis 2005, 64:iv70-iv76.
9. Warzocha K., Renard N., Charlot C., Bienvenu J., Coiffier B., Salles G. Identification of two lymphotoxin beta isoforms expressed in human lymphoid cell lines and non-Hodgkin's lymphomas. Biochem Biophys Res Commun 1997, 238:273-276.
10. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006, 6:205-217.
11. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
12. Tumanov A.V., Grivennikov S.I., Shakhov A.N., et al. Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunol Rev 2003, 195:106-116.
13. Mackay F., Browning J.L., Lawton P., et al. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterol 1998, 115:1464-1475.
14. Wu Q., Salomon B., Chen M., et al. Reversal of spontaneous autoimmune insulitis in non-obese diabetic mice by soluble lymphotoxin receptor. J Exp Med 2001, 193:1327-1332.
15. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003, 362:971-982.
16. De Bleecker J.L., Engel A.G. Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. Am J Pathol 1995, 146:1178-1187.
17. Brulé C., Dargelos E., Diallo R., et al. Proteomic study of calpain interacting proteins during skeletal muscle aging. Biochimie 2010, 92:1923-1933.
18. Smet J., Seneca S., De Paepe B. Subcomplexes of mitochondrial complex V reveal mutations in mitochondrial DNA. Electrophoresis 2009, 30:3565-3572.
19. Chen Y.W., Zhao P., Borup R., Hoffman A.P. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 2000, 151:1321-1336.
20. Banwell B.L., Engel A.G. αB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000, 54:1033-1041.
21. Lovas A., Radke D., Albrecht D., et al. Differential RelA- and RelB-dependent gene transcription in LTβR-stimulated mouse embryonic fibroblasts. BMC Genomics 2008, 16:1-20.
22. Muth I.E., Barthel K., Bähr M., Dalakas M.C., Schmidt J. Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of αB-crystallin is associated with amyloid precursor protein and accumulation of β-amyloid. J Neurol Neurosurg Psychiatry 2009, 80:1344-1349.
23. Reimann J., Schnell S., Schwartz S., Kappes-Horn K., Dodel R., Bacher M. Macrophage migration inhibitory factor in normal human skeletal muscle and inflammatory myopathies. J Neuropathol Exp Neurol 2010, 69:654-662.
24. Bansal D., Campbell K.P. Dysferlin and the plasma membrane repair in muscular dystrophy. Trends Cell Biol 2004, 14:206-213.
25. Evans N.P., Misyak S.A., Robertson J.L., Bassaganya-Riera J., Grange R.W. Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. Am J Phys Med Rehab 2009, 88:502-522.
26. Lopez J.R., Shtifman A. Intracellular β-amyloid accumulation leads to age-dependent progression of Ca2+ dysregulation in skeletal muscle. Muscle Nerve 2010, 42:731-738.
27. Tidball J.G., Wehling-Henricks M. Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events. Pediatr Res 2004, 56:831-841.
28. López-Rodríguez C., Aramburu J., Jin L., Rakeman A.S., Michino M., Rao A. Bridging the NFAT and NF-κB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress. Immunity 2001, 15:47-58.
29. Creus K.K., De Paepe B., De Bleecker J.L. Idiopathic inflammatory myopathies and the classical NF-κB complex: current insights and implications for therapy. Autoimmun Rev 2009, 2009(8):627-631.
30. Kuru S., Inukai A., Kato T., Liang V., Kimura S., Sobue G. Expression of tumor necrosis factor-α in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol 2003, 105:217-224.
31. Voon D.C., Subrata L.S., Karimi M., Ulgiati D., Abraham L.J. TNF and phorbol esters induce lymphotoxin-β expression through distinct pathways involving Ets and NF-κB family members. J Immunol 2004, 172:4332-4341.
32. Cyster J.G. Chemokines and cell migration in secondary lymphoid organs. Science 1999, 286:2098-2102.
33. Kratz A., Campos-Neto A., Hanson M.S., Ruddle N.H. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 1996, 183:1461-1472.
34. McDevitt H., Munson S., Ettinger R., Wu A. Multiple roles for tumor necrosis factor-α and lymphotoxin α/β in immunity and autoimmunity. Arthritis Res 2002, 4(Suppl. 3):S141-S152.
35. Page G., Chevrel G., Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum 2004, 50:199-208.
36. ++ transport modulation by lymphotoxin and transmembrane channel formation by antibody and nonadherent spleen cells. Ann NY Acad Sci 1979, 332:395-407.
37. De Paepe B., Schröder J.M., Martin J.J., Racz G.Z., De Bleecker J.L. Localization of the alpha-chemokine SDF-1 and its receptor CXCR4 in idiopathic inflammatory myopathies. Neuromusc Disord 2004, 14:265-273.
38. McDouall R.M., Dunn M.J., Dubowitz V. Expression of class I and class II MHC antigens in neuromuscular diseases. J Neurol Sci 1989, 89:213-226.
39. Tateyama M., Fujihara K., Misu T., Feng J., Onodera Y., Itoyama Y. Expression of CCR7 and its ligand CCL19/CCL21 in muscles of polymyositis. J Neurol Sci 2006, 249:158-165.
40. Chiang E.Y., Kolumam G.A., Yu X., et al. Targeted depletion of lymphotoxin-α-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009, 15:766-773.